News | July 20, 2021
Balaxi Pharmaceuticals Q1 revenue increases by 12%
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The company has reported total income of Rs.45.29 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
The company has reported total income of Rs.355.43 crores during FY 2020-21
The company has posted net profit of Rs.12.12 crores for the 12 months period ended March 31, 2021
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
